TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes.
Abstract
Genetic variation in the human gene encoding the lysosomal transmembrane protein 106B (TMEM106B) drives risk of neurodegenerative dementia. A C-terminal fragment of TMEM106B (TMEM CT) accumulates in lesions across neurodegenerative disease, potentially contributing to neurotoxicity and hampering efficacy of therapeutic interventions. Previously, we developed the first transgenic organism model of TMEM CT neuronal aggregation in Caenorhabditis elegans ( C. elegans ). We demonstrated that TMEM CT neuronal aggregation drives severe neuronal dysfunction and neuronal loss. To investigate the potential synergistic interaction of TMEM CT aggregation with other types of aggregated neurotoxic proteinopathies occurring in dementia, we assessed neuronal degeneration and pathogenic protein accumulation in bigenic C. elegans expressing TMEM CT and other key proteinopathies of neurodegeneration including a-synuclein, tau, and TAR DNA binding protein 43 (TDP-43). Our results showed strong neurotoxic synergy of TMEM106B with TDP-43 or α-synuclein. However, we detected only mild synergy between TMEM106B and tau. This work provides evidence in support of TMEM CT aggregation as a significant participant in the neurodegenerative process attributed to other toxic protein aggregates. The work also highlights the importance of considering secondary proteinopathy contributions including TMEM CT aggregation when developing interventions against primary TDP-43 or α-synuclein proteinopathies.
Summary Statement: This manuscript assesses the potential synergistic impact of neuronal TMEM106B C-terminal aggregation on hallmark drivers of neurodegenerative diseases like TAR DNA binding protein 43, α-synuclein, or tau.
Related
- Peptidomimetics Inspired by α-Synuclein or Its Chaperone αB-Crystallin Differentially Modulate α-Synuclein Aggregation
- The Parkinson's disease-associated A53E mutation decreases alpha-synuclein aggregation and phosphorylation in vivo
- Depletion of border-associated macrophages impairs CSF flow and exacerbates extranuclear mutant Huntingtin aggregation in the zQ175DN mouse model of Huntington’s disease
- Drosophila glutathione S-transferase S1 exacerbates phenotypes of the gain-of-function voltage-gated sodium channel mutant paraShu through a hemocyte-mediated mechanism
- Extracellular cGAMP transmission exacerbates neuroinflammation in aging and multiple sclerosis
BibTeX
@misc{riordan2026tmem106b,
title = {{TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes.}},
author = {Ruben Riordan and Aileen Saxton and Marina Han and Kailee Parrott and Brian Kraemer},
howpublished = {bioRxiv},
year = {2026},
month = oct,
doi = {10.64898/2026.10.29.762961},
url = {https://www.biorxiv.org/content/10.64898/2026.10.29.762961v1},
note = {CC0},
}
RIS
TY - UNPB
TI - TMEM106B C-Terminal fragment aggregation exacerbates α-synuclein and TDP-43 proteinopathy phenotypes.
AU - Ruben Riordan
AU - Aileen Saxton
AU - Marina Han
AU - Kailee Parrott
AU - Brian Kraemer
PY - 2026
DA - 2026/10/29
PB - bioRxiv
DO - 10.64898/2026.10.29.762961
UR - https://www.biorxiv.org/content/10.64898/2026.10.29.762961v1
AB - Genetic variation in the human gene encoding the lysosomal transmembrane protein 106B (TMEM106B) drives risk of neurodegenerative dementia. A C-terminal fragment of TMEM106B (TMEM CT) accumulates in lesions across neurodegenerative disease, potentially contributing to neurotoxicity and hampering efficacy of therapeutic interventions. Previously, we developed the first transgenic organism model of TMEM CT neuronal aggregation in Caenorhabditis elegans ( C. elegans ). We demonstrated that TMEM CT neuronal aggregation drives severe neuronal dysfunction and neuronal loss. To investigate the potential synergistic interaction of TMEM CT aggregation with other types of aggregated neurotoxic proteinopathies occurring in dementia, we assessed neuronal degeneration and pathogenic protein accumulation in bigenic C. elegans expressing TMEM CT and other key proteinopathies of neurodegeneration including a-synuclein, tau, and TAR DNA binding protein 43 (TDP-43). Our results showed strong neurotoxic synergy of TMEM106B with TDP-43 or α-synuclein. However, we detected only mild synergy between TMEM106B and tau. This work provides evidence in support of TMEM CT aggregation as a significant participant in the neurodegenerative process attributed to other toxic protein aggregates. The work also highlights the importance of considering secondary proteinopathy contributions including TMEM CT aggregation when developing interventions against primary TDP-43 or α-synuclein proteinopathies. Summary Statement: This manuscript assesses the potential synergistic impact of neuronal TMEM106B C-terminal aggregation on hallmark drivers of neurodegenerative diseases like TAR DNA binding protein 43, α-synuclein, or tau.
SN - 2692-8205
ER -